Ultragenyx Pharmaceutical
RARE
302 hedge funds and large institutions have $2.87B invested in Ultragenyx Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 131 increasing their positions, 91 reducing their positions, and 57 closing their positions.
160% more call options, than puts
Call options by funds: $88.2M | Put options by funds: $33.9M
44% more repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 91
0.5% less ownership
Funds ownership: 99.58% → 99.08% (-0.5%)
7% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 57
2% less funds holding
Funds holding: 309 → 302 (-7)
16% less capital invested
Capital invested by funds: $3.42B → $2.87B (-$551M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$55.9M |
| 3 |
RI
RTW Investments
New York
|
+$46.5M |
| 4 |
State Street
Boston,
Massachusetts
|
+$33.6M |
| 5 |
JP Morgan Chase
New York
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$61.3M |
| 2 |
ClearBridge Investments
New York
|
-$59.5M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$49.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$46.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$36.8M |
RARE Hedge Fund Activity: Q3 2025 in Review
302 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2025, worth a combined $2.87B — down 16% from $3.42B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of RARE and 53 opened new positions — a net loss of 4 holders — while 91 trimmed existing stakes and 131 added.
The largest buyer was Fidelity Investments, adding an estimated $140M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $61.3M sold.
- 302 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2025, down from 309 in Q2 2025.
- Funds reported $2.87B of Ultragenyx Pharmaceutical stock for Q3 2025, down 16% quarter-over-quarter.
- 53 funds opened new Ultragenyx Pharmaceutical positions in Q3 2025 and 57 closed out, a net change of -4 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2025 was Fidelity Investments, an estimated $140M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2025 was Alkeon Capital Management, an estimated $61.3M sold.
Based on aggregated 13F filings for Q3 2025.